1. Home
  2. KTTA vs RGNT Comparison

KTTA vs RGNT Comparison

Compare KTTA & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.80

Market Cap

19.7M

Sector

Health Care

ML Signal

HOLD

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$2.15

Market Cap

20.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KTTA
RGNT
Founded
2020
2004
Country
United States
Israel
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.7M
20.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KTTA
RGNT
Price
$0.80
$2.15
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
307.9K
6.4K
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$2.01
52 Week High
$2.06
$8.35

Technical Indicators

Market Signals
Indicator
KTTA
RGNT
Relative Strength Index (RSI) 54.86 24.88
Support Level $0.67 N/A
Resistance Level $0.87 $3.35
Average True Range (ATR) 0.06 0.17
MACD 0.00 -0.04
Stochastic Oscillator 45.64 14.53

Price Performance

Historical Comparison
KTTA
RGNT

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Share on Social Networks: